CClinicalTrials.gg
Sign In
Status unknownNCT04084327Updated Sep 10, 2019

Immunophenotyping of Acute b Cell Lymphoblstic Leukemia

An observational study in Acute Leukemia, sponsored by South Egypt Cancer Institute. Status unknown. Open to participants aged 12 Months to 80 Years. Per ClinicalTrials.gov, last updated 2019-09-10.

Sponsored by South Egypt Cancer Institute · Observational

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
50
Ages
12 Months to 80 Years
Sex
All
01

Study summary

To study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt Cancer Institute iand its correlation with disease outcome

Read the detailed description

study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt Cancer Institute from 2009 -2019 and its correlation with disease outcome

02

Conditions studied

  • Acute Leukemia

Browse trials for

03

In context

Leukemia

5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.

This study's planned enrollment of 50 is below the median of 120 across 744 observational studies indexed under Leukemia.

Browse Leukemia studies →

Lead sponsor

South Egypt Cancer Institute is the lead sponsor of 35 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

new cases Who didn't receive treatment.Age above 1 years old.

Inclusion criteria

  • New cases admitted to SECI Who didn't receive treatment.Age above 1 years old.

Exclusion criteria

Exclusion Criteria:

  • Cases who received treatment Patients below 1 years old.Patients diagnosed as AML or T-ALL
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • Otherstastical analysis

    1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results

06

What researchers measure

Primary outcomes

  1. overall survival outcome

    overall survival outcome

    Time frame: 10 years

  2. Disease-free survival outcome

    Disease-free survival outcome

    Time frame: 10 years

  3. association of novel CD markers with old markers for assessment of disease outcome

    association of novel CD markers with old markers for assessment of disease outcome

    Time frame: 10 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Keegan A, Charest K, Schmidt R, Briggs D, Deangelo DJ, Li B, Morgan EA, Pozdnyakova O. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol. 2018 Jul;71(7):653-658. doi: 10.1136/jclinpath-2017-204828. Epub 2018 Mar 27. PubMed 29588374 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04084327
Lead sponsor
South Egypt Cancer Institute
Responsible party
ayat ahmed mohamed (principle investigator, South Egypt Cancer Institute) — Principal investigator
First posted
Sep 10, 2019
Start date
Sep 1, 2019 (estimated)
Primary completion
Dec 1, 2020 (estimated)
Completion
Dec 1, 2022 (estimated)
Last update
Sep 10, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Leukemia→

Other studies from this sponsor

South Egypt Cancer Institute

Start the discussion